
Ros Deegan-Led OMass Therapeutics Raises $310 Million in One of Britain's Largest Biotech Rounds
Oxford spinout OMass Therapeutics, led by chief executive Ros Deegan, has raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to take its rare-disease drug OMS1620 into and through Phase 2.








